ZYDELIG® for relapsed follicular lymphoma

ZYDELIG is used when follicular lymphoma returns after treatment with at least 2 prior medicines. ZYDELIG was approved based on response rates. Data are not yet available to show if ZYDELIG improves symptoms or survival. ZYDELIG should not be used as the first medicine to treat people who have been diagnosed with follicular lymphoma, and should not be used in combination with bendamustine and/or Rituxan® (rituximab) to treat people with follicular lymphoma.

Although follicular lymphoma is not curable, your doctor can use different therapies or combinations of therapies to slow the growth of your follicular lymphoma cells and provide you with periods of remission.2,3

How does ZYDELIG work?

ZYDELIG works differently from chemotherapy because it blocks a specific protein in B cells called PI3K delta. PI3K delta sends signals to cancerous B cells, telling them to multiply and helping them survive. ZYDELIG blocks these signals, helping to slow the growth of lymphoma cells.4,5

Proven effective in relapsed follicular lymphoma

ZYDELIG was studied in a clinical trial of6,7:
  • 125
    people with indolent non-Hodgkin lymphoma
  • 72
    of those had relapsed follicular lymphoma7

At least 50% of the people with relapsed follicular lymphoma had been treated with 4 or more prior therapies, and all of them had relapsed within 6 months of being treated with rituximab and chemotherapy.

Of the 72 people with relapsed follicular lymphoma7:
  • 56%
    of people treated with
    ZYDELIG responded
    • 14%
      complete remission
    • 42%
      partial remission

The safety profile of ZYDELIG has also been established in people with relapsed follicular lymphoma.

View the safety profile
Image of ZYDELIG® (idelalisib) patient brochure

ZYDELIG patient brochure

The ZYDELIG patient brochure was created to provide tips on managing treatment and information about what to expect with ZYDELIG

Download PDF
Pill bottle icon


Understand your ZYDELIG dose and how to take your medication exactly as prescribed

Learn more
Call center representative icon

Financial information & nurse support

Learn more about the financial information and nurse support offerings that may be available to you while on ZYDELIG treatment

Learn more

*IntrinsiQ, May 2015 - November 2018, IMS XPO and IMS DDD data, October 2018-March 2019.


  1. ZYDELIG® (idelalisib) [prescribing information]. Foster City, CA: Gilead Sciences, Inc.; rev October 2018.
  2. Types of B-cell lymphoma. American Cancer Society website. https://www.cancer.org/cancer/non-hodgkin-lymphoma/about/b-cell-lymphoma.html. Accessed April 15, 2019.
  3. About non-Hodgkin lymphoma. American Cancer Society website. https://www.cancer.org/content/dam/CRC/PDF/Public/8717.00.pdf. Accessed April 15, 2019.
  4. Robak P, Robak T. The emerging role of ibrutinib and idelalisib in the treatment of chronic lymphocytic leukemia. J Hematol Transfus. 2013;1(1):1001.
  5. NCI Dictionary of Cancer Terms. National Cancer Institute website. https://www.cancer.gov/publications/dictionaries/cancer-terms. Accessed April 15, 2019.
  6. Gopal AK, Kahl BS, de Vos S, et al. PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med. 2014;370(11):1008-1018.
  7. Salles G, Schuster SJ, de Vos S, et al. Efficacy and safety of idelalisib in patients with relapsed, rituximab- and alkylating agent-refractory follicular lymphoma: a subgroup analysis of a phase 2 study. Haematologica. 2017;102(4):e156-e159.